StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences r&d expenses

Research and development expenses are spending on new products and technology.

Cogent Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $290.72M, up 15.9% year over year. For fiscal 2025 it was $269.78M, up 16.0% from the year before. The highest annual figure on record is $269.78M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$269.78M+16.0%
FY2024Dec 31, 2024$232.66M+33.9%
FY2023Dec 31, 2023$173.76M+42.9%
FY2022Dec 31, 2022$121.63M+117.5%
FY2021Dec 31, 2021$55.91M+117.2%
FY2020Dec 31, 2020$25.74M-41.1%
FY2019Dec 31, 2019$43.71M+14.2%
FY2018Dec 31, 2018$38.29M+28.3%
FY2017Dec 31, 2017$29.83M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$70.81M+13.8%
Q1 FY2026Mar 31, 2026$75.37M+19.6%
Q4 FY2025Dec 31, 2025$75.56M+21.8%
Q3 FY2025Sep 30, 2025$68.99M+8.4%
Q2 FY2025Jun 30, 2025$62.20M+14.6%
Q1 FY2025Mar 31, 2025$63.03M+19.6%
Q4 FY2024Dec 31, 2024$62.05M+27.4%
Q3 FY2024Sep 30, 2024$63.61M+26.9%
Q2 FY2024Jun 30, 2024$54.29M+39.7%
Q1 FY2024Mar 31, 2024$52.71M+46.2%
Q4 FY2023Dec 31, 2023$48.72M+32.6%
Q3 FY2023Sep 30, 2023$50.13M+67.4%
Q2 FY2023Jun 30, 2023$38.87M+31.9%
Q1 FY2023Mar 31, 2023$36.04M+41.5%
Q4 FY2022Dec 31, 2022$36.74M+79.1%
Q3 FY2022Sep 30, 2022$29.94M+102.3%
Q2 FY2022Jun 30, 2022$29.48M+138.0%
Q1 FY2022Mar 31, 2022$25.47M+210.1%
Q4 FY2021Dec 31, 2021$20.51M+235.9%
Q3 FY2021Sep 30, 2021$14.80M+195.8%
Q2 FY2021Jun 30, 2021$12.39M+141.5%
Q1 FY2021Mar 31, 2021$8.21M-13.5%
Q4 FY2020Dec 31, 2020$6.11M-41.0%
Q3 FY2020Sep 30, 2020$5.00M-51.6%
Q2 FY2020Jun 30, 2020$5.13M-51.7%
Q1 FY2020Mar 31, 2020$9.50M-23.4%
Q4 FY2019Dec 31, 2019$10.35M-3.8%
Q3 FY2019Sep 30, 2019$10.34M+0.8%
Q2 FY2019Jun 30, 2019$10.62M+16.3%
Q1 FY2019Mar 31, 2019$12.40M+52.3%
Q4 FY2018Dec 31, 2018$10.77M+42.4%
Q3 FY2018Sep 30, 2018$10.25M+25.4%
Q2 FY2018Jun 30, 2018$9.13M+27.8%
Q1 FY2018Mar 31, 2018$8.14M+17.1%
Q4 FY2017Dec 31, 2017$7.56M–
Q3 FY2017Sep 30, 2017$8.18M–
Q2 FY2017Jun 30, 2017$7.14M–
Q1 FY2017Mar 31, 2017$6.95M–

More Cogent Biosciences figures

See a number that looks wrong?